DataMeds AI, Inc 8-K, filed Nov 5, 2026
DataMeds AI, Inc. (MEDS)
About this 8-K
DataMeds AI, Inc filed this 8-K on November 5, 2026, reporting on events of November 3, 2026.
DataMEDS terminated its October 19, 2026 letter of intent effective November 3, 2026, citing market conditions; no shares will be issued and no fees or obligations are owed. Separate REBOOT and PharmacyChain agreements remain in force. AI summary
Items reported
- Item 1.02: Ended a material agreement
- Item 7.01: Regulation FD disclosure
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of principal executive offices, including zip code)
Registrant’s
telephone number, including area code:
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 1.02. Termination of a Material Definitive Agreement.
As previously disclosed, on October 21, 2026, DataMEDS AI, Inc. (the “Company”) entered into a Second Amended and Restated Letter of Intent, dated October 19, 2026 (the “LOI”), with EOS Technology Holdings, Inc. (“EOS”), Scilex Holding Company (“Scilex”), Datavault AI Inc. (“Datavault”), HealthBridge Advisors, LLC (“HBA”), Tollo Health, Inc. (“THI”) and REBOOT Health AI, Inc. (“REBOOT”). The LOI contemplated the acquisition of certain intellectual property assets from EOS and Scilex, the expansion of the Company’s existing PharmacyChain license with Datavault, the acquisition of a controlling interest in Tollo Health, LLC (d/b/a Health Lives Here) from HBA and THI, and intellectual property licensing and related products and services arrangements with REBOOT, in each case in exchange for the issuance of shares of the Company’s common stock.
On November 3, 2026, the Company provided written notice to EOS, Scilex, Datavault, HBA, THI and REBOOT terminating the LOI, effective immediately. The termination applies only to the LOI and does not terminate or amend any separate agreement, including any existing license agreement with Datavault, any consulting or employment arrangement or separate letters of intent between the parties. The termination does not revive any prior proposal, term sheet, letter of intent or understanding superseded by the LOI.
Item 7.01 Regulation FD Disclosure.
On November 3, 2026, the Company issued a press release announcing the termination of the LOI. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information in this Item 7.01, including Exhibit 99.1, is being furnished, not filed, pursuant to Regulation FD. Accordingly, such information will not be incorporated by reference into any registration statement filed by the Company under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated therein by reference. The furnishing of such information is not intended to, and does not, constitute a determination or admission by the Company that such information is material or complete, or that investors should consider this information before making an investment decision with respect to any security of the Company or any of its affiliates.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. | Description of Exhibit | |
| 99.1 | Press Release dated November 3, 2026. | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: November 5, 2026 | DATAMEDS AI, INC. | |
| By: | /s/ Prashant Patel | |
| Prashant Patel, President | ||
Exhibit 99.1
DataMEDS AI Announces Termination of Second Amended and Restated Letter of Intent
TAMPA, FL / ACCESS Newswire / November 3, 2026 / DataMeds AI, Inc. (“DataMeds SI,” “DataMEDS” or the “Company”) (NASDAQ:MEDS), a healthcare company that integrates its health information technology and physical infrastructure with its EinsteinRx™ artificial intelligence platform and PharmacyChain™ blockchain-enabled smart contracts platform, today announced that it has terminated the Second Amended and Restated letter of intent dated October 19, 2026 (“2nd LOI”) with Datavault AI Inc. (“Datavault AI”) (NASDAQ:DVLT), Data Health Partners, Inc.’s (“DHP”) wholly-owned subsidiary REBOOT Health AI, Inc., EOS Technology Holdings, Inc. (“EOS”), Scilex Holding Company (“Scilex”) and HealthBridge Advisors, LLC (“HealthBridge Advisors”) for the in-license or acquisition of IP in exchange for Company common stock due to market conditions. DataMEDS does not owe any fees or obligation as a result of the termination.
As a result of the termination of the 2nd LOI, DataMEDS will no longer be issuing any shares related to the 2nd LOI.
DataMEDS confirms that its exclusive license with REBOOT for the management of GLP-1 users, dated October 13, 2026, remains in full force and effect.
Datavault AI for PharmacyChain™ manufacturer-to-patient blockchain-enabled smart contracts remains in full force and effect, in accordance with the terms of that agreement dated November 24, 2025. No shares of the Company were issued to Datavault in connection with that agreement.
About DataMEDS AI
DataMEDS AI, Inc. (NASDAQ:MEDS), formerly Wellgistics Health, Inc., is a healthcare company focused on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units through its health information technology platforms to deliver a better experience for consumers and providers. Headquartered in Tampa, Fla., DataMEDS incorporates its EinsteinRx™ artificial intelligence platform and PharmacyChain™ blockchain-enabled smart contracts platform into the Health Lives Here mobile application from Tollo Health, LLC, and its pharmacy-related Corexa Health subsidiary provides pharmacy dispensing and pharmacy-related services, including distribution of products developed by Tollo Health. DataMEDS also owns Helomics Corporation, a Pittsburgh, PA-based commercial clinical molecular diagnostics laboratory focused on the ChemoFx® Assay chemotherapy selection diagnostics test that aims to help oncologists make chemotherapy treatment decisions. Learn more at https://datamedsai.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are not predictions of actual performance. Forward-looking statements include, without limitation, statements regarding: the effects of the cancellation of the LOI on the Company’s business, strategy and technology plans; the Company’s ability to identify, negotiate and complete alternative acquisitions, licenses or partnerships on acceptable terms or at all; any costs, claims or disputes that may arise in connection with the LOI or its cancellation; the status of any other existing agreements or relationships with the parties to the LOI; the Company’s capitalization and any future issuances of its securities; the Company’s ability to execute its existing business plans, including those of Health Lives Here, Corexa Health and Helomics; the Company’s ability to maintain compliance with Nasdaq listing standards; and the Company’s liquidity, capital resources and ability to fund operations. Actual results may differ materially from those expressed or implied in these forward-looking statements due to a number of risks and uncertainties, including those described under “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and subsequent filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to update or revise any forward-looking statements, except as required by law.
DataMEDS AI Media Contact
James Lambert, Vice President, Rubenstein Public Relations
212.805.3024 | jlambert@rubensteinpr.com
DataMEDS AI Investor Contact
IR@datamedsai.com